Genmab A/SNASDAQ:GMAB
- LAST PRICE28.5700
- TODAY'S CHANGE (%)0.4200 (1.4920%)
- Bid / Lots28.6600/ 1
- Ask / Lots29.3300/ 4
- Open / Previous Close28.0100 / 28.1500
- Day Range
- 52 Week Range
- Volume593,112
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GMAB |
|---|---|---|
| 09:32 ET | 10570 | 28.18 |
| 09:34 ET | 9593 | 28.25 |
| 09:36 ET | 1799 | 28.24 |
| 09:38 ET | 3300 | 28.22 |
| 09:39 ET | 2597 | 28.22 |
| 09:41 ET | 1400 | 28.21 |
| 09:43 ET | 750 | 28.23 |
| 09:45 ET | 1000 | 28.23 |
| 09:48 ET | 6303 | 28.34 |
| 09:50 ET | 100 | 28.32 |
| 09:52 ET | 1055 | 28.3 |
| 09:54 ET | 850 | 28.3 |
| 09:56 ET | 700 | 28.31 |
| 09:57 ET | 1004 | 28.3 |
| 09:59 ET | 200 | 28.3 |
| 10:01 ET | 100 | 28.32 |
| 10:03 ET | 700 | 28.36 |
| 10:06 ET | 2582 | 28.38 |
| 10:08 ET | 338 | 28.36 |
| 10:10 ET | 265 | 28.39 |
| 10:12 ET | 544 | 28.39 |
| 10:14 ET | 468 | 28.37 |
| 10:15 ET | 218 | 28.365 |
| 10:17 ET | 250 | 28.38 |
| 10:19 ET | 100 | 28.36 |
| 10:24 ET | 1000 | 28.4 |
| 10:26 ET | 250 | 28.37 |
| 10:28 ET | 200 | 28.38 |
| 10:30 ET | 701 | 28.4 |
| 10:32 ET | 100 | 28.42 |
| 10:33 ET | 400 | 28.41 |
| 10:37 ET | 193 | 28.4196 |
| 10:39 ET | 800 | 28.44 |
| 10:42 ET | 308 | 28.4 |
| 10:44 ET | 600 | 28.39 |
| 10:46 ET | 232 | 28.39 |
| 10:48 ET | 964 | 28.42 |
| 10:50 ET | 4227 | 28.38 |
| 10:51 ET | 8000 | 28.37 |
| 10:53 ET | 1750 | 28.41 |
| 10:55 ET | 24681 | 28.41 |
| 10:57 ET | 16790 | 28.43 |
| 11:00 ET | 37910 | 28.39 |
| 11:02 ET | 10460 | 28.39 |
| 11:04 ET | 3304 | 28.4 |
| 11:06 ET | 4996 | 28.37 |
| 11:08 ET | 800 | 28.36 |
| 11:09 ET | 300 | 28.36 |
| 11:11 ET | 1581 | 28.34 |
| 11:13 ET | 600 | 28.37 |
| 11:15 ET | 6548 | 28.42 |
| 11:18 ET | 3680 | 28.41 |
| 11:20 ET | 2010 | 28.35 |
| 11:22 ET | 400 | 28.34 |
| 11:24 ET | 200 | 28.35 |
| 11:26 ET | 1164 | 28.355 |
| 11:27 ET | 584 | 28.35 |
| 11:29 ET | 206 | 28.35 |
| 11:31 ET | 2951 | 28.32 |
| 11:36 ET | 500 | 28.32 |
| 11:40 ET | 1217 | 28.32 |
| 11:42 ET | 801 | 28.34 |
| 11:44 ET | 700 | 28.32 |
| 11:45 ET | 357 | 28.33 |
| 11:47 ET | 100 | 28.33 |
| 11:49 ET | 100 | 28.33 |
| 11:54 ET | 700 | 28.32 |
| 11:56 ET | 1059 | 28.32 |
| 11:58 ET | 100 | 28.32 |
| 12:00 ET | 5000 | 28.36 |
| 12:02 ET | 420 | 28.37 |
| 12:03 ET | 300 | 28.37 |
| 12:05 ET | 656 | 28.38 |
| 12:07 ET | 100 | 28.4 |
| 12:09 ET | 428 | 28.4 |
| 12:12 ET | 100 | 28.42 |
| 12:14 ET | 800 | 28.4 |
| 12:16 ET | 300 | 28.4 |
| 12:18 ET | 220 | 28.4003 |
| 12:20 ET | 1222 | 28.395 |
| 12:21 ET | 1044 | 28.405 |
| 12:23 ET | 500 | 28.376 |
| 12:25 ET | 5894 | 28.445 |
| 12:27 ET | 200 | 28.44 |
| 12:30 ET | 2850 | 28.43 |
| 12:32 ET | 4201 | 28.45 |
| 12:34 ET | 1200 | 28.455 |
| 12:36 ET | 1252 | 28.45 |
| 12:38 ET | 200 | 28.44 |
| 12:39 ET | 400 | 28.45 |
| 12:41 ET | 500 | 28.44 |
| 12:43 ET | 600 | 28.445 |
| 12:45 ET | 200 | 28.44 |
| 12:48 ET | 400 | 28.45 |
| 12:50 ET | 1000 | 28.45 |
| 12:52 ET | 1059 | 28.43 |
| 12:54 ET | 600 | 28.44 |
| 12:56 ET | 200 | 28.45 |
| 12:57 ET | 100 | 28.44 |
| 12:59 ET | 1307 | 28.47 |
| 01:01 ET | 700 | 28.46 |
| 01:03 ET | 1500 | 28.48 |
| 01:06 ET | 400 | 28.475 |
| 01:08 ET | 971 | 28.48 |
| 01:10 ET | 361 | 28.485 |
| 01:12 ET | 292 | 28.48 |
| 01:14 ET | 100 | 28.47 |
| 01:15 ET | 926 | 28.4601 |
| 01:17 ET | 100 | 28.469 |
| 01:19 ET | 800 | 28.47 |
| 01:21 ET | 1000 | 28.475 |
| 01:24 ET | 1681 | 28.48 |
| 01:26 ET | 1200 | 28.48 |
| 01:28 ET | 740 | 28.483 |
| 01:30 ET | 4150 | 28.485 |
| 01:32 ET | 100 | 28.485 |
| 01:33 ET | 1671 | 28.5 |
| 01:37 ET | 1520 | 28.49 |
| 01:42 ET | 700 | 28.495 |
| 01:44 ET | 100 | 28.495 |
| 01:46 ET | 815 | 28.49 |
| 01:48 ET | 958 | 28.46 |
| 01:50 ET | 801 | 28.489 |
| 01:51 ET | 1200 | 28.485 |
| 01:53 ET | 845 | 28.49 |
| 01:55 ET | 763 | 28.48 |
| 01:57 ET | 293 | 28.49 |
| 02:00 ET | 1007 | 28.49 |
| 02:02 ET | 1614 | 28.47 |
| 02:04 ET | 400 | 28.46 |
| 02:06 ET | 3805 | 28.49 |
| 02:08 ET | 400 | 28.49 |
| 02:09 ET | 1066 | 28.49 |
| 02:11 ET | 3250 | 28.5 |
| 02:13 ET | 8963 | 28.52 |
| 02:15 ET | 3634 | 28.54 |
| 02:18 ET | 766 | 28.545 |
| 02:20 ET | 2255 | 28.55 |
| 02:22 ET | 2643 | 28.57 |
| 02:24 ET | 800 | 28.57 |
| 02:26 ET | 300 | 28.56 |
| 02:27 ET | 490 | 28.55 |
| 02:29 ET | 314 | 28.55 |
| 02:31 ET | 1085 | 28.54 |
| 02:33 ET | 813 | 28.515 |
| 02:36 ET | 1275 | 28.52 |
| 02:38 ET | 950 | 28.53 |
| 02:40 ET | 914 | 28.52 |
| 02:42 ET | 100 | 28.55 |
| 02:44 ET | 855 | 28.55 |
| 02:45 ET | 408 | 28.555 |
| 02:49 ET | 9094 | 28.58 |
| 02:51 ET | 2663 | 28.59 |
| 02:54 ET | 865 | 28.5888 |
| 02:56 ET | 9402 | 28.63 |
| 02:58 ET | 1100 | 28.63 |
| 03:00 ET | 7369 | 28.63 |
| 03:02 ET | 4497 | 28.5881 |
| 03:03 ET | 11093 | 28.59 |
| 03:05 ET | 700 | 28.64 |
| 03:07 ET | 1782 | 28.6 |
| 03:09 ET | 300 | 28.6 |
| 03:12 ET | 2000 | 28.61 |
| 03:14 ET | 673 | 28.62 |
| 03:16 ET | 900 | 28.6 |
| 03:18 ET | 200 | 28.61 |
| 03:21 ET | 5439 | 28.62 |
| 03:23 ET | 6074 | 28.605 |
| 03:25 ET | 4342 | 28.625 |
| 03:27 ET | 1744 | 28.61 |
| 03:30 ET | 300 | 28.61 |
| 03:32 ET | 1051 | 28.6 |
| 03:34 ET | 932 | 28.61 |
| 03:36 ET | 4478 | 28.6 |
| 03:38 ET | 300 | 28.6 |
| 03:39 ET | 3436 | 28.6 |
| 03:41 ET | 9561 | 28.61 |
| 03:43 ET | 2135 | 28.595 |
| 03:45 ET | 2332 | 28.61 |
| 03:48 ET | 5000 | 28.61 |
| 03:50 ET | 2987 | 28.6 |
| 03:52 ET | 7891 | 28.62 |
| 03:54 ET | 11495 | 28.605 |
| 03:56 ET | 10606 | 28.57 |
| 03:57 ET | 13648 | 28.56 |
| 03:59 ET | 33503 | 28.57 |
Today
DJ Pfizer, Genmab Get Full FDA Approval for Cervical-Cancer Drug, from 3 hours ago by Dow Jones
3 hours ago by Dow JonesFDA Grants Full Approval for TIVDAK(R) to Treat Recurrent or Metastatic Cervical Cancer, from 3 hours ago by Dow Jones
3 hours ago by Dow JonesTIVDAK(R) (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer, from 3 hours ago by Dow Jones
3 hours ago by Dow JonesTIVDAK(R) (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer, from 3 hours ago by Dow Jones
3 hours ago by Dow Jones
Apr 4, 2024
DJ Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 11:36AM ET on Thursday Apr 04, 2024 by Dow Jones
11:36AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Genmab A/S | 18.6B | 30.2x | +22.71% |
Denali Therapeutics Inc | 2.2B | -14.3x | --- |
Arrowhead Pharmaceuticals Inc | 2.7B | -8.3x | --- |
MorphoSys AG | 2.7B | -11.6x | --- |
Galapagos NV | 1.9B | -442.7x | --- |
Amicus Therapeutics Inc | 3.0B | -19.9x | --- |
Company Information
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Contact Information
- Headquarters
- Kalvebod Brygge 43KOEBENHAVN V, Denmark 1560
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Deirdre Connelly
- President, Chief Executive Officer
- Jan Van De Winkel
- Independent Deputy Chairman of the Board
- Pernille Erenbjerg
- Chief Financial Officer, Executive Vice President
- Anthony Pagano
- Chief Operating Officer, Executive Vice President
- Anthony Mancini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.6B |
|---|---|
Revenue (TTM) | $2.4B |
Shares Outstanding | 661.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.94 |
EPS | $0.95 |
Book Value | $6.94 |
P/E Ratio | 30.2x |
Price/Sales (TTM) | 7.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 32.30% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
